CN1111529C - 作为神经激肽拮抗剂的哌嗪子基衍生物 - Google Patents
作为神经激肽拮抗剂的哌嗪子基衍生物 Download PDFInfo
- Publication number
- CN1111529C CN1111529C CN96197720A CN96197720A CN1111529C CN 1111529 C CN1111529 C CN 1111529C CN 96197720 A CN96197720 A CN 96197720A CN 96197720 A CN96197720 A CN 96197720A CN 1111529 C CN1111529 C CN 1111529C
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- reaction
- dichlorophenyl
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US308495P | 1995-08-31 | 1995-08-31 | |
US08/003,084 | 1995-08-31 | ||
CAPCT/US96/05660 | 1996-05-01 | ||
PCT/US1996/005660 WO1996034864A1 (en) | 1995-05-02 | 1996-05-01 | Piperazino derivatives as neurokinin antagonists |
US08/663,880 US5795894A (en) | 1995-05-02 | 1996-06-14 | Piperazino derivatives as neurokinn antagonists |
US08/663,880 | 1996-06-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1200120A CN1200120A (zh) | 1998-11-25 |
CN1111529C true CN1111529C (zh) | 2003-06-18 |
Family
ID=46202966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN96197720A Expired - Fee Related CN1111529C (zh) | 1995-08-31 | 1996-08-29 | 作为神经激肽拮抗剂的哌嗪子基衍生物 |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0850236B1 (hu) |
JP (2) | JP3447745B2 (hu) |
CN (1) | CN1111529C (hu) |
AT (1) | ATE202776T1 (hu) |
AU (1) | AU708834B2 (hu) |
BR (1) | BR9610277A (hu) |
CA (1) | CA2228370C (hu) |
CZ (1) | CZ22898A3 (hu) |
DE (1) | DE69613705T2 (hu) |
ES (1) | ES2158345T3 (hu) |
GR (1) | GR3036675T3 (hu) |
HU (1) | HUP9802552A3 (hu) |
IL (1) | IL123112A (hu) |
NO (1) | NO980848L (hu) |
PL (1) | PL325339A1 (hu) |
SK (1) | SK27498A3 (hu) |
WO (1) | WO1997008166A1 (hu) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5892039A (en) * | 1995-08-31 | 1999-04-06 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
US5968929A (en) * | 1996-10-30 | 1999-10-19 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
CA2269128C (en) * | 1996-10-30 | 2005-01-11 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
AUPO735997A0 (en) * | 1997-06-17 | 1997-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives |
UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
EP1047698A1 (en) * | 1998-01-14 | 2000-11-02 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
IL143577A0 (en) * | 1998-12-14 | 2002-04-21 | Fujisawa Pharmaceutical Co | Piperazine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
KR20080059687A (ko) | 2000-03-06 | 2008-06-30 | 아카디아 파마슈티칼스 인코포레이티드 | 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물 |
TW591025B (en) * | 2000-06-13 | 2004-06-11 | Fujisawa Pharmaceutical Co | Production of the piperazine derivative |
CN101050215A (zh) | 2001-12-28 | 2007-10-10 | 阿卡蒂亚药品公司 | 作为单胺受体调节剂的螺氮杂环化合物 |
US6855724B2 (en) | 2002-04-08 | 2005-02-15 | Agouron Pharmaceuticals, Inc. | Tropane derivatives useful in therapy |
US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
RU2320646C2 (ru) | 2002-06-24 | 2008-03-27 | Акадиа Фармасьютикалз Инк. | N-замещенные производные пиперидина в качестве агентов серотонинового рецептора |
US7601740B2 (en) | 2003-01-16 | 2009-10-13 | Acadia Pharmaceuticals, Inc. | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
ES2530258T3 (es) | 2004-09-27 | 2015-02-27 | Acadia Pharmaceuticals Inc. | Síntesis de una forma cristalina de sal tartrato de N-(4-fluorobencil)-N-(1-metilpiperidin-4-il)-N'-(4-(2-metilpropiloxi)fenilmetil)carbamida |
US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
WO2008090117A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
PL2134330T3 (pl) | 2007-03-19 | 2013-10-31 | Acadia Pharm Inc | Kombinacje odwrotnych agonistów i antagonistów 5-HT2A z antypsychotykami |
EP3325444B1 (en) | 2015-07-20 | 2021-07-07 | Acadia Pharmaceuticals Inc. | Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c |
WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
WO2018118626A1 (en) | 2016-12-20 | 2018-06-28 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
US11135211B2 (en) | 2017-04-28 | 2021-10-05 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
US20210077479A1 (en) | 2017-08-30 | 2021-03-18 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
CN115368296A (zh) * | 2022-07-27 | 2022-11-22 | 苏州汉德创宏生化科技有限公司 | 一种n-叔丁氧羰基-4-氨基哌啶的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2230262A (en) * | 1989-04-15 | 1990-10-17 | Scras | 2-Substituted n,n-di (trimethoxybenzoyl) piperazines |
WO1992020661A1 (en) * | 1991-05-22 | 1992-11-26 | Merck & Co., Inc. | N, n-diacylpiperazines |
US5344830A (en) * | 1992-12-10 | 1994-09-06 | Merck & Co., Inc. | N,N-diacylpiperazine tachykinin antagonists |
EP0655442A1 (en) * | 1993-11-29 | 1995-05-31 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives as Tachykinin antagonists |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5607936A (en) * | 1994-09-30 | 1997-03-04 | Merck & Co., Inc. | Substituted aryl piperazines as neurokinin antagonists |
-
1996
- 1996-05-01 BR BR9610277A patent/BR9610277A/pt not_active Application Discontinuation
- 1996-08-29 IL IL12311296A patent/IL123112A/en not_active IP Right Cessation
- 1996-08-29 HU HU9802552A patent/HUP9802552A3/hu unknown
- 1996-08-29 EP EP96931188A patent/EP0850236B1/en not_active Expired - Lifetime
- 1996-08-29 ES ES96931188T patent/ES2158345T3/es not_active Expired - Lifetime
- 1996-08-29 CZ CZ98228A patent/CZ22898A3/cs unknown
- 1996-08-29 JP JP51006997A patent/JP3447745B2/ja not_active Expired - Lifetime
- 1996-08-29 CN CN96197720A patent/CN1111529C/zh not_active Expired - Fee Related
- 1996-08-29 AT AT96931188T patent/ATE202776T1/de not_active IP Right Cessation
- 1996-08-29 PL PL96325339A patent/PL325339A1/xx unknown
- 1996-08-29 WO PCT/IB1996/001018 patent/WO1997008166A1/en not_active Application Discontinuation
- 1996-08-29 DE DE69613705T patent/DE69613705T2/de not_active Expired - Lifetime
- 1996-08-29 AU AU69979/96A patent/AU708834B2/en not_active Ceased
- 1996-08-29 SK SK274-98A patent/SK27498A3/sk unknown
- 1996-08-29 CA CA002228370A patent/CA2228370C/en not_active Expired - Fee Related
-
1998
- 1998-02-27 NO NO980848A patent/NO980848L/no not_active Application Discontinuation
-
2000
- 2000-05-24 JP JP2000153870A patent/JP3315970B2/ja not_active Expired - Fee Related
-
2001
- 2001-09-20 GR GR20010401532T patent/GR3036675T3/el not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2230262A (en) * | 1989-04-15 | 1990-10-17 | Scras | 2-Substituted n,n-di (trimethoxybenzoyl) piperazines |
WO1992020661A1 (en) * | 1991-05-22 | 1992-11-26 | Merck & Co., Inc. | N, n-diacylpiperazines |
US5344830A (en) * | 1992-12-10 | 1994-09-06 | Merck & Co., Inc. | N,N-diacylpiperazine tachykinin antagonists |
EP0655442A1 (en) * | 1993-11-29 | 1995-05-31 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives as Tachykinin antagonists |
Also Published As
Publication number | Publication date |
---|---|
HUP9802552A2 (hu) | 1999-10-28 |
JP3315970B2 (ja) | 2002-08-19 |
HUP9802552A3 (en) | 1999-11-29 |
DE69613705D1 (de) | 2001-08-09 |
EP0850236B1 (en) | 2001-07-04 |
JPH10511105A (ja) | 1998-10-27 |
CN1200120A (zh) | 1998-11-25 |
AU708834B2 (en) | 1999-08-12 |
JP2000344766A (ja) | 2000-12-12 |
CA2228370A1 (en) | 1997-03-06 |
ATE202776T1 (de) | 2001-07-15 |
WO1997008166A1 (en) | 1997-03-06 |
IL123112A0 (en) | 1998-09-24 |
BR9610277A (pt) | 1999-07-06 |
IL123112A (en) | 2001-04-30 |
JP3447745B2 (ja) | 2003-09-16 |
NO980848D0 (no) | 1998-02-27 |
CZ22898A3 (cs) | 1998-07-15 |
AU6997996A (en) | 1997-03-19 |
EP0850236A1 (en) | 1998-07-01 |
GR3036675T3 (en) | 2001-12-31 |
NO980848L (no) | 1998-04-30 |
PL325339A1 (en) | 1998-07-20 |
CA2228370C (en) | 2002-10-01 |
ES2158345T3 (es) | 2001-09-01 |
SK27498A3 (en) | 1998-12-02 |
DE69613705T2 (de) | 2002-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1111529C (zh) | 作为神经激肽拮抗剂的哌嗪子基衍生物 | |
CN1118459C (zh) | 用作α1-肾上腺素能受体拮抗剂的嘧啶二酮、嘧啶三酮、三嗪二酮衍生物 | |
CN1149209C (zh) | 与多巴胺d3受体具有亲和力的三唑化合物 | |
CN1026111C (zh) | 奎宁环衍生物的制备方法 | |
CN1189467C (zh) | 药学活性磺酰胺衍生物 | |
CN1468239A (zh) | 取代的吡唑 | |
CN1409703A (zh) | 4-氨基哌啶衍生物和它们作为药物的用途 | |
CN1088582A (zh) | 碱式季酰胺,其制备方法及其药物组合物 | |
CN1213307A (zh) | 新的取代的咪唑化合物 | |
CN1351590A (zh) | 化合物 | |
CN1330637A (zh) | 用于治疗炎性疾病的化合物 | |
CN1207730A (zh) | 喹啉衍生物 | |
CN1812980A (zh) | 哌啶基-和哌嗪基-烷基氨基甲酸酯衍生物,其制备及治疗用途 | |
CN1177828C (zh) | 新的乙内酰脲、乙内酰硫脲、嘧啶二酮和硫代嘧啶酮衍生物,制备方法和作为药物的用途 | |
CN1633414A (zh) | 化合物 | |
CN101039904A (zh) | 适于治疗对于多巴胺d3受体调节有反应的病症的杂环化合物 | |
CN87103504A (zh) | 杂环羧酰胺 | |
CN1111528C (zh) | 用作神经激肽拮抗药的哌嗪衍生物 | |
CN1585763A (zh) | 哌啶衍生物及其作为趋化因子受体(尤其是ccr5)活性调节剂的用途 | |
CN1656092A (zh) | 用于治疗炎性疾病的吗啉基-脲衍生物 | |
CN1113059C (zh) | 用作神经激肽拮抗剂的哌嗪并衍生物 | |
CN1263758C (zh) | 3,7-二氮杂双环[3.3.0]辛烷及其在治疗心脏心律失常中的用途 | |
CN1711252A (zh) | 4-(苯基-哌嗪基-甲基)苯甲酰胺衍生物及其在治疗疼痛或胃肠疾病中的用途 | |
CN1178923C (zh) | 1,4-二氮杂环庚烷-2,5-二酮衍生物及其作为nk-1受体拮抗剂的应用 | |
CN1890248A (zh) | 新化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |